Jeffrey Nornhold - Myovant Sciences President
| MYOVDelisted Stock | USD 26.98 0.01 0.04% |
President
Mr. Jeffrey D. Nornhold is Senior Vice President, Pharmaceutical Operations Development of the Company. Mr. Nornhold previously served as Senior Vice President of Technical Operations for Impax Laboratories, where he was responsible for Impax manufacturing, supply chain, quality and technical operations. Prior to that, he served as Impax Senior Vice President, Global Quality Affairs, and was responsible for establishing a sustainable quality and compliance program. Prior to Impax, Mr. Nornhold served as Vice President, Quality Operations International for Watson Pharmaceuticals, Inc., and was responsible for exU.S. manufacturing sites for both dosage and active pharmaceutical ingredients. While atWatson, he also served as Vice President, U.S. Quality Operations, where he led the development and execution of quality initiatives for all U.S. sites. Earlier in his career, he held numerous leadership positions in the pharmaceutical industry since 2018.
| Age | 57 |
| Tenure | 6 years |
| Professional Marks | MBA |
| Phone | 44 20 7400 3351 |
| Web | https://myovant.com |
Myovant Sciences Management Efficiency
The company has return on total asset (ROA) of (0.1822) % which means that it has lost $0.1822 on every $100 spent on assets. This is way below average. Myovant Sciences' management efficiency ratios could be used to measure how well Myovant Sciences manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 358.7 M in liabilities with Debt to Equity (D/E) ratio of 138.6, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Myovant Sciences has a current ratio of 1.79, which is within standard range for the sector. Debt can assist Myovant Sciences until it has trouble settling it off, either with new capital or with free cash flow. So, Myovant Sciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Myovant Sciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Myovant to invest in growth at high rates of return. When we think about Myovant Sciences' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Ronald Myers | Timken Company | 61 | |
| Patrick Maynadier | Church Dwight | 60 | |
| Dan McGrew | Eastern Co | 62 | |
| Landen Fredrick | Mannatech Incorporated | 51 | |
| Richard Simms | Rocky Brands | 50 | |
| Britta Bomhard | Church Dwight | 51 | |
| Jacquelin Brova | Church Dwight | 60 | |
| Judy Zagorski | Church Dwight | 56 | |
| Gary Adam | Rocky Brands | 52 | |
| James Levine | Church Dwight | 54 | |
| Hilik Itman | Radcom | 51 | |
| Lance Yu | Timken Company | N/A | |
| Paul Wood | Church Dwight | 48 | |
| Carlos Linares | Church Dwight | 60 | |
| Ward Timken | Timken Company | 53 | |
| Steven Cugine | Church Dwight | 57 | |
| Ronald Norman | Mannatech Incorporated | 65 | |
| Angelo Labbadia | Eastern Co | 66 | |
| John Sullivan | Eastern Co | 63 | |
| Paul Siracusa | Church Dwight | 59 | |
| Sanjay Koul | Timken Company | 60 | |
Management Performance
| Return On Asset | -0.18 |
Myovant Sciences Leadership Team
Elected by the shareholders, the Myovant Sciences' board of directors comprises two types of representatives: Myovant Sciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Myovant. The board's role is to monitor Myovant Sciences' management team and ensure that shareholders' interests are well served. Myovant Sciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Myovant Sciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Frank Karbe, Principal Financial and Accounting Officer, President and Chief Financial Officer of Myovant Sciences, Inc. | ||
| Juan Ferreira, Chief Commercial Officer - Myovant Sciences, Inc | ||
| Mark Altmeyer, Independent Director | ||
| Nancy Valente, Director | ||
| Kim Sablich, Chief Commercial Officer | ||
| Adele Gulfo, Director, Interim Chief Commercial Officer | ||
| Myrtle Potter, Chairman of the Board | ||
| Terrie Curran, Independent Director | ||
| Lauren Merendino, Chief Commercial Officer | ||
| Keith Manchester, Director | ||
| Marianne Romeo, Head, Global Transactions & Risk Management | ||
| Ann Tomlin, VP HR | ||
| Juan MD, Chief Officer | ||
| Uneek Mehra, Chief Financial and Business Officer, Principal Financial and Accounting Officer | ||
| Frank Torti, Director | ||
| Andria MD, Head Pharmacovigilance | ||
| Matthew JD, Gen Sec | ||
| Vivek Ramaswamy, Director | ||
| Jeffrey Nornhold, Senior Vice President Pharmaceutical Operations & Development | ||
| Albert Liao, Director Communications | ||
| Wayne DeVeydt, Independent Director | ||
| Matthew Lang, General Counsel, Corporate Secretary and Chief Legal and Administrative Officer and Corporate Secretary of Myovant Sciences, Inc. | ||
| Kathleen Sebelius, Lead Independent Director | ||
| Mark Guinan, Independent Director | ||
| David Marek, Principal Executive Officer, Director | ||
| Hiroshi Nomura, Director | ||
| Bryan Selby, VP Devel | ||
| Lynn Seely, Principal Executive Officer, Director |
Myovant Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Myovant Sciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.18 | |||
| Profit Margin | (0.48) % | |||
| Operating Margin | (0.39) % | |||
| Current Valuation | 2.6 B | |||
| Shares Outstanding | 97.26 M | |||
| Shares Owned By Insiders | 48.61 % | |||
| Shares Owned By Institutions | 56.21 % | |||
| Number Of Shares Shorted | 8.39 M | |||
| Price To Earning | (8.56) X | |||
| Price To Book | 70.01 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Myovant Sciences in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Myovant Sciences' short interest history, or implied volatility extrapolated from Myovant Sciences options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Other Consideration for investing in Myovant Stock
If you are still planning to invest in Myovant Sciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Myovant Sciences' history and understand the potential risks before investing.
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon |